Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bioactive lipids in schizophrenia.

Gregor E Berger1, Stefan Smesny, G Paul Amminger

  • 1ORYGEN Youth Health and ORYGEN Research Centre, Department of Psychiatry, University of Melbourne, Australia. gregor@unimelb.edu.au

International Review of Psychiatry (Abingdon, England)
|June 17, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the Relationship Between Inflammatory Biomarkers and Negative Symptoms Subtypes in Individuals at Ultra-High Risk for Psychosis.

Early intervention in psychiatry·2026
Same author

The Staging Model in Psychosis and Preventive Interventions: An Emerging Field With Debates on Conceptual Models and Interpretation of the Evidence Base.

Early intervention in psychiatry·2026
Same author

Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-Schizophrenia.

Schizophrenia bulletin·2026
Same author

Effects of 6-months of SSRI use on DNA-methylation and gene expression in blood.

Brain, behavior, and immunity·2026
Same author

Inpatient Schema Therapy: Results of a Multiple Baseline Case Series Study.

Clinical psychology & psychotherapy·2026
Same author

Altered Plasma Endocannabinoids and Oxylipins in Adolescents with Major Depressive Disorders: A Case-Control Study.

Nutrients·2026
Same journal

Continuous theta burst stimulation to the frontal pole durably decreases medial frontoamygdala connectivity.

International review of psychiatry (Abingdon, England)·2026
Same journal

What are the arguments for and against recognizing 'terminal' anorexia nervosa? A narrative review.

International review of psychiatry (Abingdon, England)·2026
Same journal

Behavioral addictions in adolescents in Latin America: a narrative review of prevalence, mental health comorbidities, and gaps in care.

International review of psychiatry (Abingdon, England)·2026
Same journal

Persistent suicidality: a concept analysis using Rodgers' evolutionary approach.

International review of psychiatry (Abingdon, England)·2026
Same journal

Extending the evidence for Scrambler Therapy to reduce pain in chemotherapy-induced peripheral neuropathy.

International review of psychiatry (Abingdon, England)·2026
Same journal

Medical assistance in dying and palliative care in Canada: clinical and ethical considerations in an evolving landscape.

International review of psychiatry (Abingdon, England)·2026
See all related articles

Bioactive lipids like arachidonic acid (AA) are crucial for brain function. Altered lipid metabolism is linked to schizophrenia, suggesting potential therapeutic targets like ethyl-eicosapentaenoic acid (E-EPA).

Area of Science:

  • Neuroscience
  • Biochemistry
  • Psychiatry

Background:

  • Bioactive lipids, especially arachidonic acid (AA), are essential for neurotransmission, brain development, and synaptic plasticity.
  • Phospholipases A2 (PLA2) enzymes are critical in AA metabolism and are activated during neurotransmission.
  • Reduced membrane AA levels and altered PLA2 activity are observed in drug-naïve schizophrenia patients.

Purpose of the Study:

  • To review the role of bioactive lipids in schizophrenia.
  • To explore the potential of lipid metabolism modulation in treating schizophrenia.
  • To investigate the efficacy of ethyl-eicosapentaenoic acid (E-EPA) in schizophrenia treatment.

Main Methods:

  • Review of existing literature on bioactive lipids and schizophrenia.

Related Experiment Videos

  • Analysis of studies using phosphorus-31 magnetic resonance spectroscopy in schizophrenia patients.
  • Examination of clinical trial data for E-EPA supplementation in schizophrenia.

    • Main Results:

    • Schizophrenia is associated with altered membrane lipid metabolism, including reduced AA levels and changes in phosphomonoesters and phosphodiesters.
    • These lipid alterations correlate with peripheral AA levels and may be linked to disease mechanisms.
    • Ethyl-eicosapentaenoic acid (E-EPA) shows modest efficacy as an add-on treatment, potentially reducing antipsychotic dosage in acutely ill patients.

    Conclusions:

    • Membrane lipid metabolism processes are implicated in psychotic disorders.
    • Modulating lipid metabolism may offer novel therapeutic strategies for schizophrenia.
    • E-EPA supplementation presents a potential adjunctive treatment for schizophrenia, particularly in acute phases.